ReviewFrontiers in pharmacology2025
Drug repurposing in traditional Chinese medicine: from empirical wisdom to modern therapeutic strategies.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Beyond metabolism and blood flow: toward an inflammation-metabolism axis paradigm for herbal medicine in obesity-related coronary heart disease.Frontiers in cardiovascular medicine · 2026Article
- Zebrafish as a translational platform for investigating multi-organ pharmacological interactions of traditional Chinese medicine.Frontiers in pharmacology · 2026Review
- Anti-inflammatory and antioxidant effects of dipotassium glycyrrhizinate in acute respiratory distress syndrome.Frontiers in medicine · 2026Article
- Integrative Traditional Chinese Medicine Strategies for Refractory Mycoplasma Pneumonia in Children: Clinical Challenges, Mechanisms, and Evidence-Based Insights.Infection and drug resistance · 2026Review
- Integration of Traditional Chinese Medicine and Psychotherapy in Mental Health: A Narrative Review of Mechanisms, Clinical Evidence, and Future Directions.Neuropsychiatric disease and treatment · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional Chinese medicine (TCM), with its multi-component and multi-target nature, offers rich potential for drug repurposing. Advances in systems biology, computational modeling, and high-throughput technologies have enabled systematic analysis of TCM mechanisms, facilitating in the identification of active ingredients, target interactions, and synergistic effects. However, most existing reviews focus on individual methods rather than providing an integrative translational strategy tailored to the complexity of TCM. This review addresses that gap by proposing a stage-based framework that combines mechanism analysis, preclinical validation, and clinical translation. We highlight key methodologies such as network pharmacology, multi-omics, molecular docking, and phenotypic screening, and discuss how they can be synergistically applied. Emerging technologies including AI, big data, 3D bioprinting, and organoid models are evaluated not only for their utility but also through critical analysis of their limitations in capturing TCM's holistic principles. By bridging traditional knowledge with modern biomedical innovation, this review offers a novel roadmap for accelerating evidence-based TCM repurposing. The proposed integrative strategy supports more reproducible, mechanistically grounded, and globally relevant applications of TCM in modern drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.